# First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

> **NCT05022030** · PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Colo-rectal Cancer
- Capecitabine
- Cetuximab

## Interventions

- **DRUG:** mCapOX plus cetuximab
- **DRUG:** mFOLFOX6 plus cetuximab

## Key facts

- **NCT ID:** NCT05022030
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-21
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05022030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05022030, "First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05022030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*